Hussman Strategic Advisors Inc. Purchases 21,000 Shares of Tempus AI, Inc. $TEM

Key Points

• Hussman Strategic Advisors doubled its stake in Tempus AI in Q4, buying an additional 21,000 shares to hold 42,000 shares valued at about $2.48 million at quarter end.
• Large holders remain active: Vanguard owns roughly 10.26 million shares (~$605.8M), while insiders have been net sellers (563,841 shares worth ~$29.9M in the past 90 days) and collectively own about 24.3% of the stock.
• Market signals are mixed: analysts carry a consensus rating of "Moderate Buy" with an average target of $71.36, but several price‑target cuts and a class‑action suit over genetic data pose downside risk, even as TIME recognition, a Keck/USC partnership and an upcoming investor day offer potential catalysts.

Hussman Strategic Advisors Inc. boosted its position in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 100.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 42,000 shares of the company's stock after purchasing an additional 21,000 shares during the period. Hussman Strategic Advisors Inc.'s holdings in Tempus AI were worth $2,480,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Tempus AI by 8.7% during the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company's stock valued at $605,772,000 after purchasing an additional 817,014 shares during the last quarter. GC Wealth Management RIA LLC bought a new position in Tempus AI during the 4th quarter valued at about $399,267,000. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Tempus AI by 1.2% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,504,823 shares of the company's stock valued at $206,960,000 after purchasing an additional 41,728 shares during the last quarter. Voloridge Investment Management LLC lifted its holdings in Tempus AI by 183.0% during the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company's stock valued at $129,708,000 after purchasing an additional 1,039,176 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in Tempus AI by 0.4% during the 3rd quarter. Franklin Resources Inc. now owns 1,456,120 shares of the company's stock valued at $117,523,000 after purchasing an additional 5,375 shares during the last quarter. 24.22% of the stock is owned by institutional investors.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Named to TIME’s 2026 list and expanded clinical reach via a multi‑year collaboration with Keck/USC — boosts brand credibility, supports commercial adoption of Tempus’ AI precision‑medicine tools and expands addressable clinical volume (coverage cites TIME recognition and the Keck Medicine partnership). TIME recognition article Keck partnership article
• Positive Sentiment: Investor‑day visibility and bullish coverage — upcoming Investor Day (management roadmap) and fresh bull writeups may attract momentum buyers and reduce execution uncertainty if management delivers concrete commercialization milestones. Investor day / bull case coverage
• Neutral Sentiment: CEO Eric Lefkofsky sold 166,250 shares under a pre‑arranged Rule 10b5‑1 plan — provides liquidity/estate planning context but can be interpreted variably by the market; sale was disclosed in an SEC filing. SEC Form 4 disclosure
• Neutral Sentiment: Analyst/valuation mix — some firms trimmed fair‑value slightly and note the recent rally may be a short‑term bounce; coverage is polarized (buy/hold/sell), so flows depend on upcoming execution/metrics. Analyst narrative article
• Negative Sentiment: Class action litigation over genetic data collection in an acquisition — proposed suits raise legal, compliance and remediation cost risk that can pressure sentiment until resolved. Class action article
• Negative Sentiment: Peer comparisons favor Illumina (ILMN) on valuation and earnings outlook — could divert institutional allocation away from TEM if investors prefer a more established genomics exposure. Peer comparison article

Insider Activity at Tempus AI

In related news, CFO James William Rogers sold 10,084 shares of Tempus AI stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $595,460.20. Following the transaction, the chief financial officer owned 101,166 shares of the company's stock, valued at $5,973,852.30. This trade represents a 9.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Eric P. Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $51.13, for a total transaction of $8,500,362.50. Following the transaction, the chief executive officer directly owned 8,841,783 shares in the company, valued at $452,080,364.79. The trade was a 1.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 563,841 shares of company stock worth $29,859,324 over the last 90 days. Insiders own 24.26% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on TEM. BTIG Research cut their price target on shares of Tempus AI from $105.00 to $90.00 and set a "buy" rating for the company in a report on Wednesday, February 25th. Guggenheim cut their price target on shares of Tempus AI from $95.00 to $60.00 and set a "buy" rating for the company in a report on Monday, March 30th. Mizuho began coverage on shares of Tempus AI in a report on Thursday, February 19th. They set an "outperform" rating and a $100.00 price target for the company. JPMorgan Chase & Co. cut their price target on shares of Tempus AI from $80.00 to $60.00 and set a "neutral" rating for the company in a report on Wednesday, February 25th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Tempus AI in a report on Thursday, January 22nd. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Tempus AI currently has a consensus rating of "Moderate Buy" and an average target price of $71.36.

Tempus AI Stock Down 0.8%

Shares of NASDAQ:TEM opened at $55.02 on Friday. Tempus AI, Inc. has a one year low of $41.73 and a one year high of $104.32. The company has a 50 day moving average of $50.65 and a 200-day moving average of $63.36. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The stock has a market cap of $9.84 billion, a price-to-earnings ratio of -39.02 and a beta of 4.00.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.